Analytical Data
-
Gene name
DEFB129
- Application
-
Alternative Names
DEFB129；C20orf87；DEFB29；Beta-defensin 129
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H1M3
-
Expression Region
20-183aa
-
AA Sequence
IGLRRCLMGLGRCRDHCNVDEKEIQKCKMKKCCVGPKVVKLIKNYLQYGTPNVLNEDVQEMLKPAKNSSAVIQRKHILSVLPQIKSTSFFANTNFVIIPNATPMNSATISTMTPGQITYTATSTKSNTKESRDSATASPPPAPPPPNILPTPSLELEEAEEQAAASFLEQKLISEEDLNSAVD
-
Molecular Weight
21.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DEFB129, a member of the defensin family of proteins, is primarily expressed in human tissues, particularly in the male reproductive system. As an antimicrobial peptide, it plays a pivotal role in the innate immune response by exhibiting broad-spectrum activity against various pathogens, including bacteria, viruses, and fungi. Research on DEFB129 has gained traction due to its potential applications in therapeutic development, specifically in enhancing immune responses and serving as a model for designing novel antimicrobial agents. Additionally, investigations into the structural properties of DEFB129 have provided insights into its mechanism of action, revealing that its efficacy stems from its ability to disrupt microbial membranes. Given the rising global concern regarding antibiotic resistance, DEFB129 presents a promising alternative in combating resistant strains. Recent studies have also explored the role of DEFB129 in reproductive health, suggesting that it may be crucial for maintaining the balance of the microflora in the male reproductive tract. Continuous research aims to elucidate the clinical implications of DEFB129, potentially leading to breakthroughs in both infectious disease management and reproductive medicine. Through recombinant protein expression systems, scientists are now able to produce DEFB129 for various experimental applications, facilitating deeper investigations into its biological functions and therapeutic potential.
